Aclaris Therapeutics (ACRS) Return on Capital Employed (2017 - 2025)
Historic Return on Capital Employed for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 0.98%.
- Aclaris Therapeutics' Return on Capital Employed fell 6800.0% to 0.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.98%, marking a year-over-year decrease of 6800.0%. This contributed to the annual value of 0.8% for FY2024, which is 3000.0% down from last year.
- Aclaris Therapeutics' Return on Capital Employed amounted to 0.98% in Q3 2025, which was down 6800.0% from 0.88% recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Return on Capital Employed ranged from a high of 0.3% in Q3 2024 and a low of 0.98% during Q3 2025
- Over the past 5 years, Aclaris Therapeutics' median Return on Capital Employed value was 0.45% (recorded in 2023), while the average stood at 0.52%.
- In the last 5 years, Aclaris Therapeutics' Return on Capital Employed surged by 6600bps in 2021 and then plummeted by -6800bps in 2025.
- Aclaris Therapeutics' Return on Capital Employed (Quarter) stood at 0.38% in 2021, then rose by 2bps to 0.38% in 2022, then tumbled by -46bps to 0.55% in 2023, then plummeted by -52bps to 0.84% in 2024, then decreased by -17bps to 0.98% in 2025.
- Its Return on Capital Employed stands at 0.98% for Q3 2025, versus 0.88% for Q2 2025 and 0.75% for Q1 2025.